EcoDrugPlus

Peroxisome Proliferator-Activated Receptor Delta-Like

Ensembl ID : ENSNBRG00000011001
Gene Symbol: LOC102791943
3 Cross references
392 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha-Like

Ensembl ID : ENSNBRG00000010818
Gene Symbol: LOC102795099
3 Cross references
202 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Beta-Like

Ensembl ID : ENSNBRG00000000914
Gene Symbol: LOC102792547
3 Cross references
189 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSNBRG00000005799
Gene Symbol: LOC102784223
3 Cross references
206 Possible Orthologues:

Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform-Like

Ensembl ID : ENSNBRG00000007112
Gene Symbol: LOC102777519
3 Cross references
211 Possible Orthologues:

Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Isoform-Like

Ensembl ID : ENSNBRG00000017863
Gene Symbol: LOC102781610
3 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSNBRG00000004608
Gene Symbol: PIK3CA
4 Cross references
208 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSNBRG00000020832
Gene Symbol: PIK3CA
4 Cross references
180 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSNBRG00000002386
Gene Symbol: PIK3CB
3 Cross references
216 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSNBRG00000013522
Gene Symbol: PDE3A
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSNBRG00000001580
Gene Symbol: PDE3A
4 Cross references
195 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSNBRG00000013064
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).